[go: up one dir, main page]

NO20074473L - RAF-inhibitorforbindelser og -fremgangsmater - Google Patents

RAF-inhibitorforbindelser og -fremgangsmater

Info

Publication number
NO20074473L
NO20074473L NO20074473A NO20074473A NO20074473L NO 20074473 L NO20074473 L NO 20074473L NO 20074473 A NO20074473 A NO 20074473A NO 20074473 A NO20074473 A NO 20074473A NO 20074473 L NO20074473 L NO 20074473L
Authority
NO
Norway
Prior art keywords
methods
inhibitor compounds
raf inhibitor
pyrazolyl compounds
compounds
Prior art date
Application number
NO20074473A
Other languages
English (en)
Norwegian (no)
Inventor
Ellen Laird
Joseph P Lyssikatos
Mike Welch
Jonas Grina
Josh Hansen
Brad Newhouse
Alan Olivero
George Topolav
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20074473L publication Critical patent/NO20074473L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
NO20074473A 2005-02-04 2007-09-03 RAF-inhibitorforbindelser og -fremgangsmater NO20074473L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65005005P 2005-02-04 2005-02-04
PCT/US2006/003654 WO2006084015A2 (fr) 2005-02-04 2006-02-02 Composes inhibiteurs de raf et procedes

Publications (1)

Publication Number Publication Date
NO20074473L true NO20074473L (no) 2007-10-31

Family

ID=36571626

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074473A NO20074473L (no) 2005-02-04 2007-09-03 RAF-inhibitorforbindelser og -fremgangsmater

Country Status (18)

Country Link
US (2) US7491829B2 (fr)
EP (1) EP1846391A2 (fr)
JP (1) JP2008530011A (fr)
KR (1) KR20070107104A (fr)
CN (1) CN101282960A (fr)
AR (1) AR053014A1 (fr)
AU (1) AU2006210626A1 (fr)
BR (1) BRPI0607346A2 (fr)
CA (1) CA2596973A1 (fr)
CR (1) CR9365A (fr)
IL (1) IL185024A0 (fr)
MA (1) MA29310B1 (fr)
MX (1) MX2007009405A (fr)
NO (1) NO20074473L (fr)
RU (1) RU2007133111A (fr)
TW (1) TW200639163A (fr)
WO (1) WO2006084015A2 (fr)
ZA (1) ZA200707289B (fr)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103739595A (zh) 2006-10-02 2014-04-23 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
MX2009004096A (es) 2006-10-17 2009-06-16 Stiefel Laboratories Metabolitos de talarozol.
US20090082354A1 (en) * 2007-09-20 2009-03-26 Wyeth Pyrazolo[5, 1-c] [1,2,4] triazines, methods for preparation and use thereof
WO2009111279A1 (fr) * 2008-02-29 2009-09-11 Array Biopharma Inc. Inhibiteurs de raf de pyrazole[3,4-b]pyridine
KR20100122505A (ko) * 2008-02-29 2010-11-22 어레이 바이오파마 인크. Ｒａｆ 저해물질 화합물 및 이들의 이용 방법
WO2009111260A1 (fr) * 2008-02-29 2009-09-11 Wyeth Pyrazolo[1,5-a]pyrimidines substituées par phénylsulfonamide, leurs procédés de préparation et leurs utilisations
WO2009108827A1 (fr) * 2008-02-29 2009-09-03 Wyeth Pyrazolo[1,5-a]pyrimidines tricycliques condensées, procédés pour les préparer et leurs utilisations
JP2011513332A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体
US20110003809A1 (en) * 2008-02-29 2011-01-06 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
JP2009286773A (ja) * 2008-03-14 2009-12-10 Bayer Cropscience Ag 殺虫性縮環式アリール類
PT2300013T (pt) 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
CA2744563A1 (fr) * 2008-12-12 2010-06-17 Ariad Pharmaceuticals, Inc. Derives d'azaindole en tant qu'inhibiteurs de kinases
EP2440058A4 (fr) 2009-06-12 2012-11-21 Dana Farber Cancer Inst Inc Composés hétérocycliques fondus et leurs utilisations
JP2013503188A (ja) 2009-08-28 2013-01-31 アレイ バイオファーマ、インコーポレイテッド Ｒａｆ阻害化合物およびその使用方法
WO2011025938A2 (fr) 2009-08-28 2011-03-03 Array Biopharma Inc. COMPOSÉS INHIBITEURS DE Raf ET LEURS PROCÉDÉS D'UTILISATION
US20120214811A1 (en) 2009-08-28 2012-08-23 Ignacio Aliagas Raf inhibitor compounds and methods of use thereof
WO2011025947A1 (fr) 2009-08-28 2011-03-03 Array Biopharma Inc. Composés inhibiteurs de raf et procédés d'utilisation de ceux-ci
US20120157451A1 (en) 2009-08-28 2012-06-21 Genentech, Inc Raf inhibitor compounds and methods of use thereof
EP2470532A1 (fr) 2009-08-28 2012-07-04 Array Biopharma, Inc. Composés 1h-pyrazolo[3,4-b]pyridines pour l'inhibition des raf kinases
JP5806672B2 (ja) * 2009-10-30 2015-11-10 ドメイン・セラピューティクス 新規オキシム誘導体及び代謝型グルタミン酸受容体のアロステリック調節因子としての利用
CA2784807C (fr) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase raf de type ii
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
US20120122928A1 (en) 2010-08-11 2012-05-17 Bayer Cropscience Ag Heteroarylpiperidine and -Piperazine Derivatives as Fungicides
EP2423210A1 (fr) 2010-08-25 2012-02-29 Bayer CropScience AG Dérivés d'hétéroarylpipéridine et -pipérazine comme fongicides
US8759527B2 (en) 2010-08-25 2014-06-24 Bayer Cropscience Ag Heteroarylpiperidine and -piperazine derivatives as fungicides
WO2012055837A1 (fr) 2010-10-27 2012-05-03 Bayer Cropscience Ag Hétéroarylpipéridine et dérivés d'hétéroarylpipéridine comme fongicide
EP2661434A4 (fr) 2011-01-06 2014-07-09 Beta Pharma Canada Inc Nouvelles urées pour le traitement et la prévention du cancer
WO2012098387A1 (fr) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Dérivés de triazolo[4,3-b]pyridazines au cycle 6,7 fusionné utilisés en tant qu'inhibiteurs de pim
WO2012104273A1 (fr) 2011-02-01 2012-08-09 Bayer Cropscience Ag Dérivés d'hétéroarylpipéridine et d'hétéroarylpipérazine utilisés comme fongicides
WO2012145503A1 (fr) 2011-04-21 2012-10-26 Novartis Ag Combinaisons pharmaceutiques
EP2704572B1 (fr) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Composés permettant d'inhiber la prolifération cellulaire dans les cancers induits par l'egfr
AR087405A1 (es) 2011-08-01 2014-03-19 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
KR20140064971A (ko) 2011-09-19 2014-05-28 제넨테크, 인크. c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료
WO2013074986A1 (fr) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibiteurs de la kinase c-jun-n-terminale (jnk)
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
EP2921481A1 (fr) 2011-12-27 2015-09-23 Bayer Intellectual Property GmbH Dérivés d'acide de 4-piperidine
EP2797888B1 (fr) * 2011-12-31 2016-06-08 BeiGene, Ltd. Composés tricycliques fusionnés à utiliser en tant qu'inhibiteurs de la kinase raf
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
KR20240146112A (ko) 2012-08-17 2024-10-07 에프. 호프만-라 로슈 아게 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
CN104994879A (zh) 2013-02-22 2015-10-21 霍夫曼-拉罗奇有限公司 治疗癌症和预防药物抗性的方法
JO3383B1 (ar) * 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
MX2015011899A (es) 2013-03-15 2016-05-05 Genentech Inc Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
WO2014206344A1 (fr) 2013-06-28 2014-12-31 Beigene, Ltd. Composés amides tricycliques condensés comme inhibiteurs de kinases multiples
ES2792183T3 (es) 2013-09-13 2020-11-10 Beigene Switzerland Gmbh Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico
EP3046557A1 (fr) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Association de rock et de la voie mapk
WO2015041534A1 (fr) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk en combinaison avec raf/erk/mek
CA2927917C (fr) 2013-10-18 2022-08-09 Syros Pharmaceuticals, Inc. Composes heteroaromatiques utiles pour le traitement des maladies proliferatives
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
EP3122900A1 (fr) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015178770A1 (fr) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions pour le traitement du cancer
JP2017517552A (ja) 2014-06-13 2017-06-29 ジェネンテック， インコーポレイテッド 抗癌剤耐性の治療及び防止方法
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
CN106604742B (zh) 2014-07-03 2019-01-11 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
AR101210A1 (es) 2014-07-15 2016-11-30 Genentech Inc Métodos de tratamiento de cáncer usando antagonistas de unión al eje pd-1 e inhibidores de mek
SG11201700496WA (en) 2014-07-22 2017-02-27 Cb Therapeutics Inc Anti-pd-1 antibodies
SG10201901057UA (en) 2014-08-05 2019-03-28 Cb Therapeutics Inc Anti-pd-l1 antibodies
EP3236959B1 (fr) 2014-12-23 2025-09-24 Dana-Farber Cancer Institute, Inc. Inhibiteurs de la kinase cycline-dépendante 7 (cdk7)
CA2978518C (fr) 2015-03-27 2023-11-21 Nathanael S. Gray Inhibiteurs de kinases cycline-dependantes
JP7320741B2 (ja) 2015-04-15 2023-08-04 ベイジーン リミテッド Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
CA2986441A1 (fr) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Therapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
JP6952691B2 (ja) 2015-11-19 2021-10-20 ジェネンテック， インコーポレイテッド Ｂ−ｒａｆ阻害剤及び免疫チェックポイント阻害剤を使用してがんを治療する方法
CN109475536B (zh) 2016-07-05 2022-05-27 百济神州有限公司 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合
PT3500299T (pt) 2016-08-19 2024-02-21 Beigene Switzerland Gmbh Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro
IL297717A (en) 2016-12-01 2022-12-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
MX2019007649A (es) * 2016-12-23 2019-09-10 Arvinas Operations Inc Compuestos y metodos para la degradacion dirigida de polipeptidos de fibrosarcoma acelerado rapidamente.
CN110461847B (zh) 2017-01-25 2022-06-07 百济神州有限公司 (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途
US11471538B2 (en) 2017-02-10 2022-10-18 INSERM (Institut National de la Santéet de la Recherche Medicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
TW202515616A (zh) 2017-06-26 2025-04-16 英屬開曼群島商百濟神州有限公司 抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途
WO2019108795A1 (fr) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Traitement de lymphomes à cellules b indolentes ou agressives au moyen d'une combinaison comprenant des inhibiteurs de btk
EP3732285A1 (fr) 2017-12-28 2020-11-04 Tract Pharmaceuticals, Inc. Systèmes de culture de cellules souches pour cellules souches épithéliales colonnaires, et leurs utilisations
WO2020005807A1 (fr) 2018-06-25 2020-01-02 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase de la famille taire et utilisations correspondantes
EP3902542A4 (fr) 2018-12-28 2022-09-07 Dana-Farber Cancer Institute, Inc. Inhibiteurs de la kinase dépendante des cyclines 7 et leurs utilisations
EP4021450B1 (fr) 2019-08-26 2025-11-05 Arvinas Operations, Inc. Procédés de traitement du cancer du sein avec des dérivés de tétrahydronaphtalène en tant qu'agents de dégradation du récepteur des oestrogènes
WO2021120890A1 (fr) * 2019-12-20 2021-06-24 Novartis Ag Dérivés pyrazolyle utiles en tant qu'agents anticancéreux
EP4204418A1 (fr) 2020-08-28 2023-07-05 Arvinas Operations, Inc. Composés de dégradation de protéine de fibrosarcome rapidement accéléré et leurs procédés d'utilisation
EP4211128A1 (fr) 2020-09-14 2023-07-19 Arvinas Operations, Inc. Formes cristallines d'un composé pour la dégradation ciblée du récepteur des oestrogènes
BR112023007912A2 (pt) * 2020-10-30 2024-01-02 Novartis Ag Formas cristalinas de um composto inibidor de kras g12c
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
KR20240090781A (ko) * 2021-11-30 2024-06-21 아비스코 테라퓨틱스 컴퍼니 리미티드 피라졸 유도체, 그 제조방법 및 약학에서의 응용
CN119301101A (zh) * 2022-07-29 2025-01-10 四川科伦博泰生物医药股份有限公司 甲基吡唑化合物、包含其的药物组合物及其制备方法和用途
TW202432544A (zh) 2022-09-07 2024-08-16 美商亞文納營運公司 快速加速纖維肉瘤降解化合物及相關使用方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1245283A (en) 1968-10-04 1971-09-08 Labaz Pyrazole derivatives
JP2753659B2 (ja) 1990-09-03 1998-05-20 株式会社大塚製薬工場 ピラゾール誘導体
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
JPH05125079A (ja) 1991-11-05 1993-05-21 Otsuka Pharmaceut Factory Inc ピラゾロ［１，５−ａピリミジン誘導体
PT714898E (pt) 1994-06-21 2002-04-29 Otsuka Pharma Co Ltd Derivado de pirazolo¬1,5-a|pirimidina
US5486534A (en) 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
CN1169149A (zh) 1995-09-28 1997-12-31 株式会社大制药工场 止痛组合物
JPH10101672A (ja) 1996-08-06 1998-04-21 Otsuka Pharmaceut Factory Inc アデノシン増強剤
JPH10101671A (ja) 1996-08-08 1998-04-21 Otsuka Pharmaceut Factory Inc 一酸化窒素合成酵素阻害剤
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
RU2249591C2 (ru) 1997-05-22 2005-04-10 Дж.Д. Серл Энд Ко. 3(5)-гетероарилзамещенные пиразолы в качестве ингибиторов киназы p38
JP2000153671A (ja) 1998-11-20 2000-06-06 Fuji Photo Film Co Ltd 感熱記録材料
EP1173254A2 (fr) 1999-04-27 2002-01-23 Smithkline Beecham Plc Nouveau traitement de conditions neurotraumatiques avec un inhibiteur de raf
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
CA2369076A1 (fr) 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Compositions de pyrazole utiles en tant qu'inhibiteurs d'erk
AU2001236720A1 (en) 2000-02-05 2001-08-14 Bemis, Guy Compositions useful as inhibitors of erk
CZ20013540A3 (cs) 2000-02-05 2002-03-13 Vertex Pharmaceuticals Incorporated Deriváty pyrazolu jako inhibitory ERK a farmaceutický prostředek, který je obsahuje
JP2003525936A (ja) 2000-03-06 2003-09-02 スミスクライン ビーチャム パブリック リミテッド カンパニー Ｒａｆキナーゼ阻害物質としてのイミダゾール誘導体
CA2423154A1 (fr) 2000-09-21 2002-03-28 David Kenneth Dean Derives d'imidazole en tant qu'inhibiteurs de la raf kinase
KR100843281B1 (ko) 2000-12-28 2008-07-09 오노 야꾸힝 고교 가부시키가이샤 삼환식 복소환 유도체 화합물 및 그 화합물을 유효성분으로 하는 의약
ES2296910T3 (es) 2001-01-22 2008-05-01 Sankyo Company, Limited Compuestos sustituidos con grupo amino biciclicos.
CA2440211A1 (fr) * 2001-03-09 2002-09-19 Pfizer Products Inc. Composes de benzimidazole anti-inflammatoires
EP1382603B1 (fr) 2001-04-26 2008-07-23 Eisai R&D Management Co., Ltd. Compose azote a anneaux condenses possedant un groupe pyrazolyle et servant de substituant, et composition medicale le comprenant
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
ES2289116T3 (es) * 2001-05-24 2008-02-01 Eli Lilly And Company Nuevos derivados de pirrol como agentes farmaceuticos.
CA2456187A1 (fr) 2001-08-03 2003-02-13 Qing Tang Inhibiteurs de kinase derives du pyrazole et leurs utilisations
WO2003011855A2 (fr) 2001-08-03 2003-02-13 Vertex Pharmaceuticals Incorporated Inhibiteurs de kinase derives du pyrazole et leurs utilisations
GB0121490D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Ciompounds
GB0121494D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
US6897208B2 (en) 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
US20040010027A1 (en) 2001-12-17 2004-01-15 Pharmacia & Upjohn Spa Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them
JP4286146B2 (ja) * 2001-12-18 2009-06-24 メルク エンド カムパニー インコーポレーテッド メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピラゾール系調節剤
JP4399265B2 (ja) * 2001-12-21 2010-01-13 ヴァーナリス（ケンブリッジ）リミテッド ３，４−ジアリールピラゾール、および癌の治療におけるそれらの使用
ATE365740T1 (de) 2002-05-10 2007-07-15 Smithkline Beecham Corp Substituierte pyrazolopyrimidine
GB0217786D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
TW200417547A (en) 2002-07-31 2004-09-16 Smithkline Beecham Corp Compounds
DE60309342T2 (de) * 2002-08-09 2007-05-16 Eli Lilly And Co., Indianapolis Benzimidazole und benzothiazole als inhibitoren der map-kinase
US6967254B2 (en) 2002-09-09 2005-11-22 Amgen Inc. Substituted heterocyclic compounds and methods of use
EP1543001B1 (fr) 2002-09-17 2007-08-15 Eli Lilly And Company Derives de pyrazolopyridine en tant qu'inhibiteurs de tgf-beta pour le traitement des maladies de cancer
BR0314302A (pt) 2002-09-18 2005-07-05 Pfizer Producs Inc Compostos de pirazol como inibidores do fator de crescimento trnasformante (tgf)
WO2004026302A1 (fr) 2002-09-19 2004-04-01 Eli Lilly And Company Procedes relatifs a l'inhibition du tgf-beta par le biais de pyrazoles substitues
AU2003290734A1 (en) * 2002-11-27 2004-06-23 Eli Lilly And Company Novel compounds as pharmaceutical agents
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
GB0313915D0 (en) * 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds

Also Published As

Publication number Publication date
AU2006210626A1 (en) 2006-08-10
BRPI0607346A2 (pt) 2009-09-01
CA2596973A1 (fr) 2006-08-10
CR9365A (es) 2008-01-15
EP1846391A2 (fr) 2007-10-24
JP2008530011A (ja) 2008-08-07
US7491829B2 (en) 2009-02-17
TW200639163A (en) 2006-11-16
MA29310B1 (fr) 2008-03-03
IL185024A0 (en) 2007-12-03
US20060189627A1 (en) 2006-08-24
RU2007133111A (ru) 2009-03-10
US20090176809A1 (en) 2009-07-09
AR053014A1 (es) 2007-04-18
MX2007009405A (es) 2007-09-25
KR20070107104A (ko) 2007-11-06
WO2006084015A3 (fr) 2006-11-23
CN101282960A (zh) 2008-10-08
WO2006084015A2 (fr) 2006-08-10
ZA200707289B (en) 2009-09-30

Similar Documents

Publication Publication Date Title
NO20074473L (no) RAF-inhibitorforbindelser og -fremgangsmater
NO20081595L (no) Raf-inhibitorforbindelser og fremgangsmater for anvendelse derav
NO20076553L (no) RAF-inhibitorforbindelser og fremgangsmater for anvendelse derav
NO20084183L (no) Heterobisykliske pyrazolforbindelser og fremgangsmater for anvendelse
WO2008028141A3 (fr) Composés inhibiteurs de la kinase raf et procédés d'utilisation de ceux-ci
NO20091198L (no) Azabenzotiofenylforbindelser og anvendelser derav
NO20091197L (no) Azabenzofuranylforbindelser og anvendelser derav
WO2009111278A3 (fr) Composés inhibiteurs de kinases raf et procédés d'utilisation
SG178986A1 (en) 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
PH12013502369A1 (en) Diazacarbazoles and methods of use
WO2010003022A8 (fr) Dérivés d'isoindolone utilisés en tant qu'inhibiteurs de kinase mek et procédés d'utilisation correspondants
NO20084927L (no) Fosfoinositid-3-kinaseinhibitorforbindelser og farmasoytiske sammensetninger inneholdende dem
DK2231662T3 (da) 8-Anilinoimidazopyridiner og deres anvendelse som anticancer- og/eller antiinflammatoriske midler
SG178899A1 (en) Raf inhibitor compounds and methods of use thereof
PH12013501779B1 (en) Pyrrolopyridines as kinase inhibitors
ECSP10010507A (es) Pirazolo (3, 4-b) piridina inhibidores de raf
UA111756C2 (uk) Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
NO20083572L (no) Tiazolforbindelser som proteinkinase-B (PKB)-inhibitorer
MX338504B (es) Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso.
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
NO20084928L (no) Farmasoytiske sammensetninger
NO20092651L (no) Dihydropyridinderivater som er anvendelige som proteinkinaseinhibitorer
MY158829A (en) 5-anilinoimidazopyridines and methods of use
MX2011009167A (es) Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapeuticos para el tratamiento contra neoplasia hemotopoyeticas malignas.
ATE516286T1 (de) 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application